COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASE
Antibodies and compositions against IGF-1R and uses thereof are provided herein.
1 .- 47 . (canceled)
48 . A method of treating thyroid eye disease by inhibiting insulin-like growth factor I receptor (IGF-IR) activity in a subject in need thereof, the method comprising:
administering a first dose of a pharmaceutical composition comprising an antibody at a dose of 10 mg/kg to the subject in need thereof;
administering a second dose of the pharmaceutical composition comprising the antibody at a dose of 10 mg/kg to the subject 3 weeks after the first dose; and
administering three or more subsequent doses of the pharmaceutical composition comprising the antibody at a dose of 10 mg/kg to the subject every 3 weeks,
wherein the antibody comprises a light chain variable region having the amino acid sequence of SEQ ID NO: 13 and a heavy chain variable region having the amino acid sequence of SEQ ID NO: 14.
49 . The method of claim 48 , wherein the subject is administered the pharmaceutical composition for a total of 5 doses to about 8 doses.
50 . The method of claim 49 , wherein the subject is administered the pharmaceutical composition for a total of 5 doses.
51 . The method of claim 49 , wherein the subject is administered the pharmaceutical composition for a total of 8 doses.
52 . The method of claim 48 , wherein the antibody comprises a light chain having the amino acid sequence of SEQ ID NO: 93 and a heavy chain having the amino acid sequence of SEQ ID NO: 92.
53 . The method of claim 49 , wherein the antibody comprises a light chain having the amino acid sequence of SEQ ID NO: 93 and a heavy chain having the amino acid sequence of SEQ ID NO: 92.
54 . The method of claim 50 , wherein the antibody comprises a light chain having the amino acid sequence of SEQ ID NO: 93 and a heavy chain having the amino acid sequence of SEQ ID NO: 92.
55 . The method of claim 51 , wherein the antibody comprises a light chain having the amino acid sequence of SEQ ID NO: 93 and a heavy chain having the amino acid sequence of SEQ ID NO: 92.
56 . The method of claim 48 , wherein the pharmaceutical composition is administered intravenously or subcutaneously.
57 . The method of claim 56 , wherein the pharmaceutical composition is administered intravenously.
58 . The method of claim 56 , wherein the pharmaceutical composition is administered subcutaneously.
59 . The method of claim 48 , wherein treating the thyroid eye disease reduces proptosis in an eye in the subject.
60 . The method of claim 49 , wherein treating the thyroid eye disease reduces proptosis in an eye in the subject.
61 . The method of claim 50 , wherein treating the thyroid eye disease reduces proptosis in an eye in the subject.
62 . The method of claim 51 , wherein treating the thyroid eye disease reduces proptosis in an eye in the subject.
63 . The method of claim 59 , wherein proptosis is reduced by at least 2 mm.
64 . The method of claim 48 , wherein treating the thyroid eye disease reduces clinical activity score (CAS) in the subject.
65 . The method of claim 48 , wherein treating the thyroid eye disease reduces proptosis by at least 2 mm and reduces clinical activity score (CAS) of the subject.
66 . The method of claim 48 , wherein treating the thyroid eye disease improves or reduces the severity of diplopia in the subject.
67 . The method of claim 66 , wherein the diplopia is constant diplopia, inconstant diplopia, or intermittent diplopia.